It was just a week when I wrote that Teva Pharmaceutical (NYSE:TEVA) seemed undervalued on the basis of its probable free cash flow (FCF)
trajectory, but that a host of uncertainties (including its strategic
direction/priorities) made it a tough stock to love. Wednesday's
announcement of a U.S. marketing partnership with Alexza (Nasdaq:ALXA)
for the controversial inhaled acute agitation therapy Adusave is a good
case-in-point. While Teva may see a diamond in the rough here, a lot of
investors and analysts are going to look at this as a sign that the
company is flailing around in search of a new direction and embracing
longshots as a strategy.
Continue reading here:
http://www.investopedia.com/stock-analysis/050913/adasuve-deal-very-good-alexza-what-about-teva-alxa-teva-vrx-bmy-lly.aspx
No comments:
Post a Comment